by telrheum | Apr 23, 2024 | Biologic Therapy, Il-6 inhibitors, Infections, JAK Inhibitor
This article, “Risk of Hepatitis B Virus Reactivation in Patients with Rheumatoid Arthritis Receiving JAK Inhibitor or IL-6 Inhibitor: A Systematic Review and Meta-Analysis” by Akhil Sood, Janice Lin, and Neha Shah from Stanford University, presents a study that looks...
by telrheum | Apr 21, 2024 | Biologic Therapy, Immunoglobulins, Infections
The study titled “Risk of Severe Infections Associated with Immunoglobulin Deficiency Under Rituximab Therapy in Immune Mediated Inflammatory Diseases” conducted by Claire Rempenault and colleagues, explored the connection between severe infections and...
by telrheum | Apr 21, 2024 | Lupus, Hydroxychloroquine
The study discussed in the article focuses on the prevalence and risk factors associated with retinal toxicity in patients using hydroxychloroquine (HCQ) for over five years, primarily for autoimmune diseases. This medication is generally safe but has been linked to...
by telrheum | Apr 21, 2024 | Lupus, Malignancy
The article titled “Incidence of and Risk Factors for Myelodysplastic Syndromes in Patients with Rheumatologic Diseases” by YoungEun Kim and colleagues focuses on the connection between rheumatologic diseases and myelodysplastic syndromes (MDS), a type of...
by telrheum | Apr 7, 2024 | Biologic Therapy, Rheumatoid Arthritis
This article discusses a phase 3 clinical trial on telitacicept, a drug designed to treat rheumatoid arthritis (RA) in patients who have not responded well to methotrexate (MTX). Telitacicept is a recombinant fusion protein that targets and neutralizes two molecules,...